204 related articles for article (PubMed ID: 32020477)
41. Targeting glutamine metabolism exhibits anti-tumor effects in thyroid cancer.
Zhang GQ; Xi C; Ju NT; Shen CT; Qiu ZL; Song HJ; Luo QY
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38386265
[TBL] [Abstract][Full Text] [Related]
42. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Casper E
Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
[TBL] [Abstract][Full Text] [Related]
43. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast.
Willis RC; Seegmiller JE
J Cell Physiol; 1977 Dec; 93(3):375-82. PubMed ID: 22551
[TBL] [Abstract][Full Text] [Related]
44. Influence of 6-diazo-5-oxo-L-norleucine (DON), a glutamine analogue, on cartilaginous differentiation in mouse limb buds in vitro.
Aydelotte MB; Kochhar DM
Differentiation; 1975 Oct; 4(2):73-80. PubMed ID: 1183764
[TBL] [Abstract][Full Text] [Related]
45. L-glutaminase and L-asparaginase by extracorporeal route in acute lymphoblastic leukemia therapy.
Giordano C; Esposito R; Mazzola G; Vecchio G; Pluvio M; Cirillo D; Capasso GB; Buonanno G
Int J Artif Organs; 1981 Sep; 4(5):244-8. PubMed ID: 6947966
[TBL] [Abstract][Full Text] [Related]
46. An inhibitor of human asparagine synthetase suppresses proliferation of an L-asparaginase-resistant leukemia cell line.
Gutierrez JA; Pan YX; Koroniak L; Hiratake J; Kilberg MS; Richards NG
Chem Biol; 2006 Dec; 13(12):1339-47. PubMed ID: 17185229
[TBL] [Abstract][Full Text] [Related]
47. Mutagenicity of O-diazoacetyl-L-serine (azaserine) and 6-diazo-5-oxo-L- norleucine (DON) in a soybean test system.
Katoh Y; Maekawa M; Sano Y
Mutat Res; 1995 Mar; 342(1-2):37-41. PubMed ID: 7885392
[TBL] [Abstract][Full Text] [Related]
48. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
49. Selective apoptosis of natural killer-cell tumours by l-asparaginase.
Ando M; Sugimoto K; Kitoh T; Sasaki M; Mukai K; Ando J; Egashira M; Schuster SM; Oshimi K
Br J Haematol; 2005 Sep; 130(6):860-8. PubMed ID: 16156856
[TBL] [Abstract][Full Text] [Related]
50. Transport and membrane binding of the glutamine analogue 6-diazo-5-oxo-L-norleucine (DON) in Xenopus laevis oocytes.
Taylor PM; Mackenzie B; Hundal HS; Robertson E; Rennie MJ
J Membr Biol; 1992 Jun; 128(3):181-91. PubMed ID: 1501246
[TBL] [Abstract][Full Text] [Related]
51. Limb development in mouse embryos: protection against teratogenic effects of 6-diazo-5-ox-L-norleucine (DON) in vivo and in vitro.
Greene RM; Kochhar DM
J Embryol Exp Morphol; 1975 Apr; 33(2):355-70. PubMed ID: 1176851
[TBL] [Abstract][Full Text] [Related]
52. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
[TBL] [Abstract][Full Text] [Related]
53. Effect of 6-diazo-5-oxo-L-norleucine (DON) on human carcinoid tumor cell aggregates.
Wu F; Bergström M; Stridsberg M; Orlefors H; Eriksson B; Oberg K; Watanabe Y; Långstrom B
Anticancer Res; 1997; 17(4A):2363-7. PubMed ID: 9252648
[TBL] [Abstract][Full Text] [Related]
54. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
[TBL] [Abstract][Full Text] [Related]
55. Asparaginase in the treatment of non-ALL hematologic malignancies.
Emadi A; Zokaee H; Sausville EA
Cancer Chemother Pharmacol; 2014 May; 73(5):875-83. PubMed ID: 24515335
[TBL] [Abstract][Full Text] [Related]
56. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
57. β-Elemene inhibits proliferation through crosstalk between glia maturation factor β and extracellular signal‑regulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells.
Zhu TZ; Li XM; Luo LH; Xu YH; Cao P; Liu Y; Liang GB
Mol Med Rep; 2014 Aug; 10(2):1122-8. PubMed ID: 24866280
[TBL] [Abstract][Full Text] [Related]
58. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
59. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
[TBL] [Abstract][Full Text] [Related]
60. Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Cervantes-Madrid D; Romero Y; Dueñas-González A
Biomed Res Int; 2015; 2015():690492. PubMed ID: 26425550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
